Extensively Drug-resistant Tuberculosis
📧 Sign up to get email alerts when something new happens for Extensively Drug-resistant Tuberculosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-11-22FDA Approved: PRETOMANID — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Pretomanid submitted by Viatris Specialty LLC, updating its labeling to reflect its use in drug-…
-
FDA approval · 2022-12-21FDA Approved: PRETOMANID — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Pretomanid, submitted by Viatris Specialty LLC.
-
FDA approval · 2019-08-14FDA Approved: PRETOMANID — Original Application (Viatris Specialty LLC)
FDA approved pretomanid under NDA 212862 from Viatris Specialty LLC. The approval addresses treatment options for drug-resistant tuberculosi…
-
CLINICAL_TRIALS approval · 2017-11-27Clinical Trial Update: Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis
The document notes marketing approval for TMC207 (bedaquiline) to treat extensively drug-resistant or pre-XDR pulmonary tuberculosis through…